The CARE Technology Lanka (Pvt) Ltd of The Institute for Combinatorial Advanced Research and Education of KDU (KDU-CARE) entered into a research service agreement with Interpharm (Pvt) Ltd, on the 25th November 2022, to conduct the Bioequivalence (BE) study of Gliclazide MR 60 mg manufactured by the Gamma Interpharm (Pvt) Ltd. Major General Milinda Peiris, the Vice-Chancellor, Prof. Thushara Weerawardane, Director/ KDU-CARE/Managing Director CTL, Institute of Combinatorial Advanced Research and Education (KDU-CARE), signed the agreement on behalf of General Sir John Kotelawala Defence University. Mr. Kalana Hewamallika, Chairman/Managing Director, and of Mrs. S. L. Sivayogarajan –Director of operations of Gamma Interpharm (Pvt) Ltd., signed the agreement on behalf of Gamma Interpharm (Pvt) Ltd. C. A. Munisinghe – General Manager (Quality Assurance), D.R.P. Perera -General Manager (Production) represented the Gamma Interpharm (Pvt) Ltd. on this occasion., Snr. Prof Rohini Fernandopulle – WHO National Consultant on Regulatory Functions to N MRA, Prof. Charitha Gunasekara – Former Acting Director, KDU-CARE, Dr. Himali Jayasinghearachchi, Principal Investigator-Analytical, Dr. Nadeesha Ratwadu-Co-Investigator- Analytical, and Dr Pandula Athauda-arachchi,-Principle Investigator (Clinical)/Consultant Interventional Cardiologist (UK & SL Board Certified) and Clinical investors of the project Dr. Janaka Munasinghe, Dr. Priyamali Jayesekara, Dr. Dumitha Govindapala -Consultant Physicians(University Hospital KDU)), also participated in this occasion.
In addition, The CARE Technology Lanka (Pvt) Ltd (CTL) of the Institute for Combinatorial Advanced Research and Education (KDU-CARE) of KDU has successfully completed the Bioequivalence (BE) study on Metformin extended-release for Gamma Interpharm (Pvt) Ltd. The final report was submitted by the Vice-Chancellor of KDU Major General Milinda Peiris to Mr. Kalana Hewamallika-Chairman/Managing Director of Gamma Interpharm (Pvt) Ltd.